Table 1 Epitopes and cross reactivities of selected antibodies raised against Aβ

4G8

Raised against synthetic peptide Aβ17-24; epitope lies within aa 18–23; recognises multiple forms of Aβ

Cross reacts with APP770 and P3; reacts with conformational epitope of aggregated fibrils including α-synuclein

[2,3,4]

6E10

Raised against Aβ1-17; epitope lies within aa 4–9; recognises Aβ with intact N-terminal epitope

Cross reacts with APP and Aβ(1–16); No reaction predicted with P3

[2, 5]

6F3D

Raised against synthetic peptide Aβ8-17; epitope lies within aa 10–15; recognises Aβ with intact N-terminal epitope

Predicted to react with Aβ(1–16); Does not react with P3

[2, 6]

MBC40

(Aβ40)

Recognises C-terminal Aβ peptides ending at aa40; epitope not well described

Cross reacts with N-terminal truncated peptides including P3

[2]

MBC42

(Aβ42)

Recognises C-terminal Aβ peptides ending at aa42; epitope not well described

Cross reacts with N-terminal truncated peptides including P3

[2]

BS85

Raised against Aβ(25–35); recognises Aβ38, Aβ39, Aβ40, Aβ42 and Aβ43; epitope not well described

Cross reacts with N-terminal truncated peptides including P3

[2]

BC05

Raised against Aβ(35–43); recognises Aβ42 and Aβ43; epitope not well described

Cross reacts with N-terminal truncated peptides including P3; does not recognise Aβ40; used in commercial ELISA kits for the detection of Aβ42

[7, 8]

BA27

Raised against Aβ(1–40) Recognises Aβ40; 100-1000x more reactive with Aβ40 than Aβ42 and Aβ43; epitope not well described

Cross reacts with N-terminal truncated peptides including P3; used in commercial ELISA kits for the detection of Aβ40

[7]

AβN17

(Leu)

Raised against P3(40); recognises P3(40) and synthetic P3(42) peptide; epitope not well described

Reactivity with insoluble, aggregated P3(42) not confirmed

[7, 9, 10]

3D6

Raised against Aβ with N-terminal aspartic acid; epitope lies within aa 1–5; recognises multiple C-terminal variations

Does not cross react with sAPPs or full length APP; No reactivity with N-terminally altered Aβ; No reaction predicted with P3; parent of Bapineuzumab

[11,12,13]

266

Raised against synthetic Aβ; epitope lies within aa 13–28; recognises soluble monomer and multiple C-terminal variations

Cross reacts with various plasma proteins containing the core sequence KLVFF; does not cross react with P3; parent of Solanezumab

[11,12,13,14]